The case for testing and treating all HBV patients
Homie Razavi(Center for Disease Analysis), Erkin Musabaev(Hai phong University Of Medicine and Pharmacy), Shokhista Bakieva(Center for Disease Analysis), Rick Dunn, Shakhlo Sadirova(Tashkent Chemical-Technological Institute), Kathryn Razavi‐Shearer(Center for Disease Analysis)
Cited by 4
Related Papers
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
|Journal of Hepatology|2018|2k
Global epidemiology and genotype distribution of the hepatitis C virus infection
|Journal of Hepatology|2014|1.9k
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484